Skip to main content
Clinical Trials/NCT03841331
NCT03841331
Completed
Phase 2

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin

Vyne Therapeutics Inc.41 sites in 1 country233 target enrollmentJanuary 22, 2019

Overview

Phase
Phase 2
Intervention
5 mg Serlopitant Tablets
Conditions
Pruritus
Sponsor
Vyne Therapeutics Inc.
Enrollment
233
Locations
41
Primary Endpoint
Worst Itch Numeric Rating Scale 4-point Responder Rate at Week 10
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin

Registry
clinicaltrials.gov
Start Date
January 22, 2019
End Date
January 21, 2020
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

5 mg Serlopitant Tablets

Serlopitant Tablets

Intervention: 5 mg Serlopitant Tablets

5 mg Placebo Tablets

Placebo Tablets

Intervention: Matching Placebo Tablets

Outcomes

Primary Outcomes

Worst Itch Numeric Rating Scale 4-point Responder Rate at Week 10

Time Frame: At Week 10

During the study, Worst Itch Numeric Rating Scale (WI-NRS) assessments was reported by the subject via eDiary. The daily NRS results were summarized. The daily results were averaged to create weekly measures. The Itch NRS is a validated, self-reported, instrument for measurement of itch intensity. It used a 24-hour recall period and asked subjects to rate the intensity of their itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable), higher scores indicated greater itch intensity. A subject was a 4-point responder if their change from baseline is ≤ -4 (i.e. a decrease of at least 4).

WI-NRS 4-point Responder Rate at Weeks 2 4, 6, and 8

Time Frame: At Weeks 2, 4, 6, and 8

During the study, Worst Itch Numeric Rating Scale (WI-NRS) assessments was reported by the subject via eDiary. The daily NRS results were summarized. The daily results were averaged to create weekly measures. The Itch NRS is a validated, self-reported, instrument for measurement of itch intensity. It used a 24-hour recall period and asked subjects to rate the intensity of their itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable), higher scores indicated greater itch intensity. A subject was a 4-point responder if their change from baseline is ≤ -4 (i.e. a decrease of at least 4).

WI-NRS 3-point Responder Rate at Weeks 2, 4, 6, 8, and 10

Time Frame: At Weeks 2, 4, 6, 8, and 10

During the study, Worst Itch Numeric Rating Scale (WI-NRS) assessments was reported by the subject via eDiary. The daily NRS results were summarized. The daily results were averaged to create weekly measures. The Itch NRS is a validated, self-reported, instrument for measurement of itch intensity. It used a 24-hour recall period and asked subjects to rate the intensity of their itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable), higher scores indicated greater itch intensity. A subject was a 3-point responder if their change from baseline is ≤ -3 (i.e. a decrease of at least 3). Results presented below is of subjects who were a 3-point responder but not a 4-point responder.

Change From Baseline in WI-NRS at Weeks 2, 4, 6, 8, and 10

Time Frame: At Weeks 2, 4, 6, 8, and 10

During the study, Worst Itch Numeric Rating Scale (WI-NRS) assessments was reported by the subject via eDiary. The daily NRS results were summarized. The daily results were averaged to create weekly measures. The Itch NRS is a validated, self-reported, instrument for measurement of itch intensity. It used a 24-hour recall period and asked subjects to rate the intensity of their itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable), higher scores indicated greater itch intensity.

Change From Baseline in Daily WI-NRS Scores Through Week 2

Time Frame: Through 2 weeks

During the study, Worst Itch Numeric Rating Scale (WI-NRS) assessments was reported by the subject via eDiary. The daily NRS results were summarized. The daily results were averaged to create weekly measures. The Itch NRS is a validated, self-reported, instrument for measurement of itch intensity. It used a 24-hour recall period and asked subjects to rate the intensity of their itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable), higher scores indicated greater itch intensity.

Change From Baseline in Worst-Itch Visual Analog Scale at Weeks 2, 4, 6, and 10

Time Frame: At Weeks 2, 4, 6, and 10

The Itch Visual Analog Scale (VAS) is a validated, self-reported instrument for measurement of itch intensity. It used a 24-hour recall period and asked subjects to rate the worst intensity of their itch on a 100-mm horizontal line ranging from 0 mm (no itch) to 100 mm (worst itch imaginable). Higher scores indicated greater itch intensity. The VAS measurement were summarized in centimeters. WI-VAS assessments were reported by the subject via a paper form administered at study visits.

Secondary Outcomes

  • Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)(From screening until the Follow-up (F/U) visit which occurred 35 days (+ 7 days) after the Week 10 visit or the last dose of study drug for subjects who discontinued study drug early.)
  • Plasma Concentrations of Serlopitant and Metabolites(At Week 10)

Study Sites (41)

Loading locations...

Similar Trials